provides patent protection of resulting Products through at least 2035.

The company's technology employs an enzymatic modification of naturally occurring glycan anchor points found on all antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry, allowing clinicians to design complex biological drugs without the need for prior genetic modifications.